Companies

Investigation Into BioAge Labs: Deadline for Investors Approaching

Published January 7, 2025

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In BioAge To Contact Him Directly To Discuss Their Options

If you suffered losses exceeding $75,000 in BioAge between September 26, 2024 and January 7, 2025, you may want to consider discussing your legal rights. Reach out to Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

You may also click here for additional information

NEW YORK, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a prominent national securities law firm, is currently investigating potential claims against BioAge Labs, Inc. ("BioAge" or the "Company") (NASDAQ:BIOA). This investigation serves as a reminder for investors that the deadline to apply for the role of lead plaintiff in a federal securities class action against the Company is set for March 10, 2025.

Established in 1995, Faruqi & Faruqi, LLP has offices across New York, Pennsylvania, California, and Georgia, and has been involved in recovering hundreds of millions of dollars for investors. For more information, you can visit their website at www.faruqilaw.com.

The core of the complaint alleges that BioAge and its executives breached federal securities laws by disseminating information that was found to be false and/or misleading regarding its STRIDES Phase 2 clinical trial.

On September 27, 2024, BioAge completed its initial public offering, offering 12.65 million shares at a price of $18 per share. The IPO included a full exercise of the underwriters' option to purchase an additional 1.65 million shares.

However, by December 6, 2024, just a few months later, BioAge revealed that it would stop the ongoing STRIDES Phase 2 study of its investigational drug candidate, azelaprag, due to instances of liver transaminitis observed in some participants. An analyst noted this revelation as surprising, considering that liver toxicity had not been an issue in the eight Phase 1 trials previously conducted by BioAge.

Following this announcement, BioAge's stock price dropped significantly, falling from $20.09 per share on December 6, 2024, to just $4.65 per share by December 9, 2024.

The role of lead plaintiff is generally filled by the investor who has the largest financial stake in the outcome of the case and is representative of the interests of other members of the class. Any putative class member may move to serve as lead plaintiff with the legal help of their choosing, or they may opt to remain an absent class member. It is important to note that your ability to claim any recovery is not influenced by whether you choose to act as a lead plaintiff.

Faruqi & Faruqi, LLP also invites anyone with information about BioAge's conduct to come forward, including whistleblowers, former employees, shareholders, and others.

To learn more about the BioAge Labs class action, please visit www.faruqilaw.com/BIOA or call Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

Attorney Advertising: Faruqi & Faruqi, LLP is responsible for this advertisement. Prior outcomes do not ensure a similar result in future cases. We are available to discuss your specific situation, and all communications will be kept confidential.

investigation, securities, lawsuit